Results: There were statistically significant differences between the control group and type 1 diabetes mellitus during the measurements of FVC%, FEV1/FVC% and MMFR%, with statistically significant reductions in their values when compared to controls. Furthermore, type 2 diabetes mellitus has significant effects on FVC%, FEV1 and FEV1/FVC% when compared with the controls, with statistically significant differences from the control group. There were no much differences between them apart from the FVC% which favors type 1 diabetes mellitus over type 2 diabetes mellitus with highly significant P-value. Conclusion: The present study clearly indicates that both type 1 and type 2 diabetes mellitus adversely affects the various pulmonary function tests, and the results are in accord with other previous studies.
he lung can be considered as one of the end organs which can be adversely affected by diabetes; reduced lung function may occasionally be present even before the clinical recognition of diabetes although it will not be the presenting symptom (1) , suggesting that the lung may be involved in the pathogenesis of diabetes.
There is growing evidence which supports the association between reduced lung function and diabetes (2) . The improvements in lung function following intensive insulin therapy (3) support the concept that the lung may be a target organ for damage in diabetes. Diabetes has been associated with asthma at the population level (4) , suggesting that despite their immunological differences, susceptibility to diabetes and asthma may be influenced by common environmental factors. The large size alveolar-capillary network is protected against gross respiratory complications at a given level of systemic microvascular destruction. Therefore lung function tests could provide useful measures to follow the progress of systemic microangiopathy in diabetics. (5) In diabetic patients forced expiratory volume in the first second (FEV1) declines at twice the physiological rate regardless of the presence of documented autonomic neuropathy. (6) Patients with diabetes without a smoking history or clinical lung disease consistently demonstrate a modest restrictive ventilator defect with proportional (8-20%) reductions in lung volume, forced vital capacity (FVC), FEV1, and forced expiratory flow in the midrange of vital capacity compared to subjects without diabetes (7) and in relation to glycemic control. (8) Total lung capacity, lung elastic recoil, and dynamic lung compliance were abnormally reduced in type 1 diabetes.
The aims of this study are to measure the effects of type 1 and type 2 diabetes mellitus on the various spirometric tests and also to study the effect of the duration of diabetes mellitus, the age and sex of the patient on these various tests.
Patients and methods
This study involved 70 diabetic patients 25 type 1 and 45 type 2 diabetes mellitus, and 45 control group. Type 1 diabetic patients included 14 men and 11 women, their ages ranging from 17-63 years with their mean 47.12 with SD 12.83. Type 2 diabetic patients included 26 men and 19 women; their ages ranging from 19-63 years with their mean 46.67 and with SD 9.50. The control group involved 24 men and 21 women, their ages ranging from 13-68 years with their mean 38.78 with SD13.3. The exclusion criteria were as follows: Patients with known history of acute or chronic respiratory infections which may interfere with lung function tests, neuromuscular disease, cardiopulmonary disease and those who had undergone chest surgery or other major operations. Subjects with history of smoking and patients with gross abnormalities of the thoracic cage which may interfere with lung function test were also excluded from the study. Furthermore patients with overt diabetic neuropathy, retinopathy and nephropathy were also excluded from the study.
All the spirometric measurements were carried out in the outpatient department of IbnSena Teaching Hospital during the early morning, while the subjects were in standing position. All the measurements were done by T using DISCOM 14 Spirometer (Germany 
Statistical analysis
The various lung function tests were reported in absolute volume as well as the per cent of their predicted values, the percent of predicted values were mostly used in the statistical analysis. After calculation of the mean and the standard deviation, the statistical analysis was conducted using unpaired T-test to compare the lung function tests values in type 1 and type 2 diabetes mellitus with the control group. The level of significance was taken as p<0.025.
Results
To study the effects of diabetes mellitus on the various lung function tests, we compared the effects of type 1 diabetes mellitus on the lung function tests by comparing it with the control group as in table (1) .
There were statistically significant differences between the control group and type 1 diabetes mellitus during the measurements of FVC%, FEV1/FVC% and MMFR%, with statistically significant reductions in their values when compared with the controls. These results prove that type 1 diabetes mellitus patients have significant effects on the various lung function tests as restrictive pulmonary defect and even obstructive ventilator defect.
Furthermore, we compared the effects of type 2 diabetes mellitus on the lung function tests by comparing it with the control group as in table (2) . These results asserting that type 2 diabetes mellitus has significant effects on many lung function tests as compared with the controls, especially during the measurements of FVC%, FEV1 and FEV1/FVC% with statistically significant differences between the control group and type 2 diabetes mellitus, with statistically significant reductions in the value of these tests when we compare them with the control group. All these result go with restrictive pulmonary defect. To determine the difference between type 1 and type 2 diabetes mellitus and their effects on the various lung function tests, we studied the differences between them as in table (3) by using unpaired T-test, this type of study indicates that there were no much differences between them apart from the FVC% which favors type 1 diabetes mellitus over type 2 diabetes mellitus with highly significant P-value as shown below in table (3) . This test indicates that type 1 and type 2 diabetes mellitus have similar effect on the various lung function tests. The duration of diabetes in the two groups seems to have no significant effects on the lung function tests values, as most of the patients in the sample studied had their diabetes mellitus duration less than 10 years, apart from 5 patients in type 1 and 5 patients in type 2 diabetes mellitus as seen in table (4). 
Discussion
Pulmonary indices are largely independent of physical fitness and the secondary sequel of diabetic end-organ failure usually does not interfere with the interpretation of the various lung function tests (10) . Therefore this study depends on spirometric measurement to assess the effect of diabetes mellitus on lung function test. Williams JG and others since 1984 demonstrated that more than one third of patients with diabetes showed abnormal ventilator response to exercise, hypercapnia, or hypoxia consistent with autonomic neuropathy. (5) The present study demonstrates that type 1 diabetes mellitus has significant effects on the lung function tests during the measurements of FVC%, FEV1/FVC% and MMFR%, with statistically significant reductions in their values when compared with the controls, but FEV1% and PEFR% were more or less the same as the control group. These results are consistent with the findings by Sandler M and others (11) . However, Benbassat and coworkers showed that FVC, FEV 1 , and MMFR% were within the predicted values in both type 1 and type 2 diabetes populations (12) .
Furthermore they compared the effects of type 1 and type 2 diabetes mellitus on the various lung function tests and they showed nonsignificant differences in FEV 1 and MMFR%, but they did not compare their results with the matched control group, this is the most probable reason for this contradiction with the present study (12) .
Furthermore type 2 diabetes mellitus, as demonstrated in this study, has significant effects on many lung function tests as compared with the controls, especially during the measurements of FVC%, FEV1 and FEV1/FVC% with statistically significant reductions in the value of these tests. These abnormalities in the lung function tests in this study were the same as what Davis WA and others founds in their study (7) .
When we compared the effects of type 1 and type 2 diabetes mellitus on the various lung function tests, there were no much differences between them apart from the FVC% which favors type 1 diabetes mellitus over type 2 diabetes mellitus with highly significant Pvalue.
This test indicates that type 1 and type 2 diabetes mellitus have more or less similar effects on the various lung function tests.
These findings were the same as in other studies (13, 14) .
The duration of diabetes in the two groups in the present study seems to have no significant effects on the lung function tests values as most of the patients in the sample studied had their diabetes mellitus duration less than 10 years apart from 5 patients in type 1 and 5 patients in type 2 diabetes mellitus. Meo SA et al demonstrated in their study that the duration of diabetes in both type 1 and type 2 diabetes mellitus had no significant effects on the lung function tests when the duration of diabetes mellitus is less than 10 years. On the other hand, when the duration of diabetes was more than 10 years or particularly more than 12 years they found statistically significant effects on the various lung function tests (15) .
The present study clearly indicates that both type 1 and type 2 diabetes mellitus adversely affect the various pulmonary function tests, and the results are in accord with other previous studies. Analysis of our data demonstrated poor correlation between the number of years of diabetes mellitus and the decline in lung function tests, mostly due to the fact that most of the patients in the present study had their disease for less than 10 years. Even though it is advisable that physicians should think about the lungs as potential targets for end-organ damage in diabetes. For these reasons it is recommended that patients with diabetes should have periodic spirometry measurement to assess their extent of impaired pulmonary function. These measures will recognize early stages of pulmonary defect, which will help to lower the morbidity and mortality of diabetes.
Conclusion
Type 1 and type 2 diabetes mellitus adversely affect the various pulmonary function tests. Both types of diabetes cause restrictive ventilator defect. It is probably useful that patients with diabetes should have periodic spirometry measurement to assess the extent of impairment in the pulmonary function tests. These measures will recognize early stages of pulmonary defect, which may help to lower the morbidity and mortality of patients with diabetes secondary to lung function defect.
